Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2933 (LINC02933)
- Target
- LINC02933
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA), Other (non-protein coding RNA family)
01
Overview
Long intergenic non-protein coding RNA 2933 (LINC02933, also known as AC012213.3) is a member of the long intergenic non-coding RNA (lincRNA) family, characterized as a non-protein coding RNA transcript longer than 200 nucleotides and not overlapping with annotated protein-coding genes. LINC02933 is catalogued in human genome databases, but its specific biological role is not well documented and there are currently no established therapeutic, diagnostic, or biomarker utilities. Like other lincRNAs, it may possess gene regulatory functions such as chromatin remodeling or enhancer activity, but these have not been directly assigned to LINC02933 in published literature[1][3][7].
- Other names
- AC012213.3
02
Mechanism of action
Not applicable for LINC02933; as an lincRNA, its mechanisms may include *cis* and *trans* regulation of neighboring gene expression, enhancer-mediated activity, chromatin and nuclear architecture modulation, generally sequence-dependent or sequence-independent regulatory functions
03
Biological functions
There is no direct evidence for specific biological functions of LINC02933 itself.Chromatin remodelingGenome architecture regulationRegulation of gene expression (transcriptional modulation, enhancer activity)RNA stabilization
04
Disease associations
Cancer (as an lncRNA family member, lincRNAs have roles in gene regulation impacting cancer biology; a specific PubMed-cited study mentions AC012213.3/LINC02933 overexpression promoting breast cancer cell proliferation, migration, and invasion)Other (lincRNAs implicated in development and diverse diseases, but no evidence for LINC02933 in other pathologies)
05
Safety considerations
None known; as LINC02933 is not a therapeutic target, there are no safety concerns documented in the context of drug targeting
06
Interacting drugs
No known drugs directly interact with LINC02933; long non-coding RNAs are rarely direct drug targets
07
Biomarkers
No clinical biomarkers are established for LINC02933 patient selection or efficacy monitoring
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2933 (LINC02933).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2933 (LINC02933).